Immunotherapy in Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

Immunotherapy in Triple-Negative Breast Cancer

Published:2021-01 Issue:1 Volume:27 Page:59-66
ISSN:1540-336X
Container-title:The Cancer Journal
language:en
Short-container-title:Cancer J

Author:

Emens Leisha A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference29 articles.

1. The evolving management of metastatic triple negative breast cancer;Semin Oncol,2020

2. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation;N Engl J Med,2017

3. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation;N Engl J Med,2018

4. Sacituzumab govitecan-hziy in refractor metastatic triple negative breast cancer;N Engl J Med,2019

5. Sacituzumab govitecan in previously treated hormone receptor–positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial;Ann Oncol,2020

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability;Acta Pharmaceutica Sinica B;2024-08

2. Targeting Hypoxia and HIF1α in Triple-Negative Breast Cancer: New Insights from Gene Expression Profiling and Implications for Therapy;Biology;2024-07-31

3. CDCA5 accelerates progression of breast cancer by promoting the binding of E2F1 and FOXM1;Journal of Translational Medicine;2024-07-08

4. Detailed role of SR-A1 and SR-E3 in tumor biology, progression, and therapy;Cell Biochemistry and Biophysics;2024-06-17

5. Recent Developments in Combination Immunotherapy with Other Therapies and Nanoparticle-Based Therapy for Triple-Negative Breast Cancer (TNBC);Cancers;2024-05-25